Clinical Cancer Research The Science of Cancer Health Disparities
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Etienne, M. C.
Right arrow Articles by Milano, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Etienne, M. C.
Right arrow Articles by Milano, G.

Clinical Cancer Research, Vol 4, Issue 10 2383-2390, Copyright © 1998 by American Association for Cancer Research


ARTICLES

Epidermal growth factor receptor and labeling index are independent prognostic factors in glial tumor outcome

MC Etienne, JL Formento, C Lebrun-Frenay, J Gioanni, M Chatel, P Paquis, C Bernard, A Courdi, RJ Bensadoun, JP Pignol, M Francoual, P Grellier, M Frenay and G Milano
Centre Antoine Lacassagne, Nice, France.

The aim of this study was to perform a multivariate analysis including clinical and biological prognostic factors on glial tumor outcome. Seventy-nine patients were analyzed (48 men and 31 women; mean age = 56 years, range = 16-77 years): 7 had a benign glial tumor (grades 1 and 2), 21 had an anaplastic glial tumor (grade 3), and 51 had a glioblastoma (grade 4). Median follow-up was 17.9 months for patients who survived (50 patients died). Biopsies were obtained at time of diagnosis (complete tumor resection in 62 patients and stereotaxic biopsies in 17 patients). Epidermal growth factor receptor (EGFR) was measured by a binding assay, and labeling index (LI) was measured by tritiated thymidine incorporation. EGFR varied from 4 to 73,110 fmol/mg protein (mean = 3912 fmol/mg protein; median = 374 fmol/mg protein; n = 79). LI varied between 0.1 and 16.5% (mean = 6.2%; median = 5.2%; n = 40). Log10 EGFR was significantly and positively correlated with patient age. LI was significantly different according to tumor histology. Univariate Cox analysis (end point was cancer death) showed that age (P = 0.027), log10 EGFR (P = 0.025), and LI (P = 0.0019) were significant continuous variables, the survival being shortened when the covariable increased; tumor resection (P = 0.015, relative risk = 0.45) and histology (P = 0.0009) were significant categorical factors. A multivariate Cox analysis (forward selection) including age, histology, tumor resection, log10 EGFR, and LI revealed that log10 EGFR, LI, and tumor resection were the only independent significant predictors of survival. This multivariate approach reveals that the clinical prognostic factors of glial tumors, namely age and tumor histology, disappear, to the benefit of intrinsic characteristics of the tumor, i.e., EGFR expression and LI, suggesting that coupled EGFR and LI determination could be a useful tool for better evaluation of glial tumor outcome.


This article has been cited by other articles:


Home page
BrainHome page
D. Krex, B. Klink, C. Hartmann, A. von Deimling, T. Pietsch, M. Simon, M. Sabel, J. P. Steinbach, O. Heese, G. Reifenberger, et al.
Long-term survival with glioblastoma multiforme
Brain, October 1, 2007; 130(10): 2596 - 2606.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. Aghi, P. Gaviani, J. W. Henson, T. T. Batchelor, D. N. Louis, and F. G. Barker II
Magnetic Resonance Imaging Characteristics Predict Epidermal Growth Factor Receptor Amplification Status in Glioblastoma
Clin. Cancer Res., December 15, 2005; 11(24): 8600 - 8605.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. B. Heimberger, R. Hlatky, D. Suki, D. Yang, J. Weinberg, M. Gilbert, R. Sawaya, and K. Aldape
Prognostic Effect of Epidermal Growth Factor Receptor and EGFRvIII in Glioblastoma Multiforme Patients
Clin. Cancer Res., February 15, 2005; 11(4): 1462 - 1466.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. B. Heimberger, E. C. McGary, D. Suki, M. Ruiz, H. Wang, G. N. Fuller, and M. Bar-Eli
Loss of the AP-2{alpha} Transcription Factor Is Associated with the Grade of Human Gliomas
Clin. Cancer Res., January 1, 2005; 11(1): 267 - 272.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
P. Leuraud, L. Taillandier, J. Medioni, L. Aguirre-Cruz, E. Criniere, Y. Marie, M. Kujas, J.-L. Golmard, A. Duprez, J.-Y. Delattre, et al.
Distinct Responses of Xenografted Gliomas to Different Alkylating Agents Are Related to Histology and Genetic Alterations
Cancer Res., July 1, 2004; 64(13): 4648 - 4653.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
A. Chakravarti, G. Zhai, Y. Suzuki, S. Sarkesh, P. M. Black, A. Muzikansky, and J. S. Loeffler
The Prognostic Significance of Phosphatidylinositol 3-Kinase Pathway Activation in Human Gliomas
J. Clin. Oncol., May 15, 2004; 22(10): 1926 - 1933.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
N. Shinojima, K. Tada, S. Shiraishi, T. Kamiryo, M. Kochi, H. Nakamura, K. Makino, H. Saya, H. Hirano, J.-i. Kuratsu, et al.
Prognostic Value of Epidermal Growth Factor Receptor in Patients with Glioblastoma Multiforme
Cancer Res., October 15, 2003; 63(20): 6962 - 6970.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
T. F. Liu, S. B. Tatter, M. C. Willingham, M. Yang, J. J. Hu, and A. E. Frankel
Growth Factor Receptor Expression Varies among High-Grade Gliomas and Normal Brain: Epidermal Growth Factor Receptor Has Excellent Properties for Interstitial Fusion Protein Therapy
Mol. Cancer Ther., August 1, 2003; 2(8): 783 - 787.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
H. Ding, P. Shannon, N. Lau, X. Wu, L. Roncari, R. L. Baldwin, H. Takebayashi, A. Nagy, D. H. Gutmann, and A. Guha
Oligodendrogliomas Result from the Expression of an Activated Mutant Epidermal Growth Factor Receptor in a RAS Transgenic Mouse Astrocytoma Model
Cancer Res., March 1, 2003; 63(5): 1106 - 1113.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
E. C. Burton, K. R. Lamborn, P. Forsyth, J. Scott, J. O'Campo, J. Uyehara-Lock, M. Prados, M. Berger, S. Passe, J. Uhm, et al.
Aberrant p53, mdm2, and Proliferation Differ in Glioblastomas from Long-Term Compared with Typical Survivors1
Clin. Cancer Res., January 1, 2002; 8(1): 180 - 187.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. Chakravarti, M. A. Delaney, E. Noll, P. McL. Black, J. S. Loeffler, A. Muzikansky, and N. J. Dyson
Prognostic and Pathologic Significance of Quantitative Protein Expression Profiling in Human Gliomas
Clin. Cancer Res., August 1, 2001; 7(8): 2387 - 2395.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
H. Ding, L. Roncari, P. Shannon, X. Wu, N. Lau, J. Karaskova, D. H. Gutmann, J. A. Squire, A. Nagy, and A. Guha
Astrocyte-specific Expression of Activated p21-ras Results in Malignant Astrocytoma Formation in a Transgenic Mouse Model of Human Gliomas
Cancer Res., May 1, 2001; 61(9): 3826 - 3836.
[Abstract] [Full Text]


Home page
Clin. Cancer Res.Home page
J. Grill, V. W. Van Beusechem, P. Van Der Valk, C. M. F. Dirven, A. Leonhart, D. S. Pherai, H. J. Haisma, H. M. Pinedo, D. T. Curiel, and W. R. Gerritsen
Combined Targeting of Adenoviruses to Integrins and Epidermal Growth Factor Receptors Increases Gene Transfer into Primary Glioma Cells and Spheroids
Clin. Cancer Res., March 1, 2001; 7(3): 641 - 650.
[Abstract] [Full Text]


Home page
Cancer Res.Home page
M. L. Simmons, K. R. Lamborn, M. Takahashi, P. Chen, M. A. Israel, M. S. Berger, T. Godfrey, J. Nigro, M. Prados, S. Chang, et al.
Analysis of Complex Relationships between Age, p53, Epidermal Growth Factor Receptor, and Survival in Glioblastoma Patients
Cancer Res., February 1, 2001; 61(3): 1122 - 1128.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1998 by the American Association for Cancer Research.